Welcome to our dedicated page for ZGNX news (Ticker: ZGNX), a resource for investors and traders seeking the latest updates and insights on ZGNX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZGNX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZGNX's position in the market.
Zogenix (NASDAQ: ZGNX) announced on September 15, 2021, that its compensation committee granted inducement awards to 14 new employees under the 2021 Employment Inducement Equity Incentive Award Plan. These awards include options to purchase 45,100 shares of common stock and 22,600 restricted stock units, with options priced at $14.69 per share. The options vest over four years, starting with a 25% vesting on the first anniversary, followed by monthly vesting. Zogenix focuses on therapies for rare diseases, including FINTEPLA, approved for treating Dravet syndrome.
Zogenix is advancing its plans to submit a new drug application (J-NDA) for FINTEPLA in Japan to treat seizures caused by Dravet syndrome by year-end. The Japanese Ministry of Health has granted FINTEPLA Orphan Drug Designation, indicating a critical need for effective treatments for this severe, treatment-resistant epilepsy. Approximately 3,000 patients in Japan suffer from Dravet syndrome, highlighting the potential market. The company is also collaborating with Nippon Shinyaku for distribution if approved.
Zogenix announced the granting of inducement awards to fourteen new employees on August 15, 2021. The compensation committee approved these awards under the company’s 2021 Employment Inducement Equity Incentive Award Plan. The total awards include options to purchase 34,580 shares of Zogenix common stock at an exercise price of $13.75 and 17,340 restricted stock units. The options vest over four years, with 25% vesting annually. Zogenix is focused on developing therapies for rare diseases, including its FDA-approved therapy FINTEPLA for Dravet syndrome.
Zogenix, a biopharmaceutical firm, reported Q2 2021 financial results, highlighting substantial growth in product sales. Total revenue reached $18.8 million, up 37% from Q1, driven by net product sales of $17.5 million for FINTEPLA, representing a 42% increase. As of June 30, 2021, over 860 patients were prescribed FINTEPLA, and 290 prescribers were noted, marking a 22% rise. The company is progressing on NDA submissions for FINTEPLA and MT1621, with expectations to launch in Japan and further expansions in Europe.
Zogenix, a biopharmaceutical company focused on rare diseases, will feature its CEO, Stephen J. Farr, Ph.D., and CFO, Michael Smith, in a virtual fireside chat on August 10, 2021, at 10:30 AM ET during the BofA SMID Cap 2H21 Ideas Conference. The event will be webcast live and archived for 90 days on Zogenix's Investor Relations website. The company is known for its FDA-approved therapy, FINTEPLA, for Dravet syndrome, and is advancing additional programs in related rare diseases.
Zogenix (NASDAQ: ZGNX) will report its Q2 2021 financial results and host a conference call on August 5, 2021, at 4:30 PM ET. The company focuses on developing therapies for rare diseases, including its approved drug FINTEPLA for Dravet syndrome. Zogenix is also advancing late-stage programs for Lennox-Gastaut syndrome and TK2 deficiency, along with a planned study for CDKL5 Deficiency Disorder. The call will provide insights into the company's financial performance and future strategies.
Zogenix, a biopharmaceutical company, has launched VIP Siblings, a website designed to support siblings of adolescents with rare epilepsy. In collaboration with ten advocacy groups, the initiative aims to address the emotional strain these siblings experience, often feeling neglected due to their sibling's condition. The resources include educational materials and tools for both parents and siblings. This effort reflects findings from Zogenix's Siblings Voices Study, highlighting that over 50% of siblings reported feelings of unhappiness and irritability.
Zogenix (NASDAQ: ZGNX) announced management participation in two investor conferences: the Raymond James Human Health Innovation Conference on June 23, 2021, focusing on epilepsy treatment advancements, and the SVB Leerink CNS Forum on June 29, 2021, discussing underappreciated assets. Presenters include Michael Smith, CFO, and Stephen Farr, CEO. Zogenix is committed to therapies for rare diseases, with FDA-approved FINTEPLA for Dravet syndrome and ongoing development for other conditions like Lennox-Gastaut syndrome.
Zogenix, a biopharmaceutical company focused on rare diseases, announced a virtual fireside chat featuring CEO Stephen J. Farr and CFO Michael Smith on May 13, 2021, at 3:30 PM ET during the BofA Securities 2021 Healthcare Conference. The event will be webcast live and archived for 90 days on Zogenix's Investor Relations website. Zogenix is known for its first therapy, FINTEPLA, which treats Dravet syndrome. The company is also advancing therapies for Lennox-Gastaut syndrome and TK2 deficiency, alongside development initiatives with Tevard Biosciences for genetic epilepsies.
